DIVI S LABORATORIES LTD

Divi's Laboratories Limited held an earnings conference on August 1, 2026, to discuss its financial results for the quarter ended June 30, 2026. Management reported a consolidated total income of ₹3,144 crores, up from ₹2,529 crores year-over-year, with profit before tax increasing to ₹1,180 crores compared to ₹733 crores in the previous year. The company highlighted stable volumes in its Generic business, while pricing faced competitive pressures. Management noted ongoing investments in manufacturing capabilities and technology development, particularly in peptides and custom synthesis. The external operating environment remained challenging, particularly due to geopolitical factors affecting supply chains. Management emphasized the importance of maintaining supply continuity and strategic inventory buffers. The discussion included insights into the company's capital expenditure projects, which are nearing completion, and the ongoing commitment to corporate social responsibility initiatives. The session concluded with a Q&A segment addressing various operational and financial queries from participants.

The document presented both positive financial results and challenges in the operating environment.